

Appl. No. : 09/581,651  
Filed : October 10, 2000

## SUMMARY OF INTERVIEW

### Identification of Claims Discussed

All the pending claims were discussed with respect to issues relating to 35 U.S.C. §§ 112, 102, and 103. In particular, claim language of Claims 1 and 10 were discussed. Claim 1 is directed to a polynucleotide. Claim 10 is directed to a polypeptide. The Examiner acknowledged that Claims 4 and 5 are allowed.

### Proposed Amendments and Principal Arguments

Applicants proposed amending Claim 1 to recite a portion of polynucleotide sequence that encodes a unique tail of MSF, namely "VSIPPRNLGY." This unique tail is believed to be patentable over the cited prior art. Applicants proposed removing the terms "variants thereof," "fragments thereof," and "derivatives" to overcome the rejections under 35 U.S.C. § 112, first paragraph.

Applicants proposed amending Claim 10 to recite a portion of the polypeptide sequence of SEQ ID NO.1 from residues 19-660. This portion is believed to be patentable over the cited prior art. As with Claim 1, Applicants proposed removing the terms "variants thereof," "fragments thereof," and "derivatives" to overcome the rejections under 35 U.S.C. § 112, first paragraph.

### Results of Interview

Applicants agreed to file an Amendment which would include the proposed amendments discussed during the interview.

Appl. No. : 09/581,651  
Filed : October 10, 2000

**BEST AVAILABLE COPY**

#### **REMARKS**

Claims 1, 2, 4, 5, 8-11, 29, 36-38, 40-42, 47, 51, 53, 56, and 58 have been amended and Claims 6, 12, 13, 27, 57, and 59 have been cancelled without prejudice. As a result, Claims 1-5, 7-11, 29, 36-42, 44, 47-51, 53, 56, and 58 remain pending in the present application. Support for the amendments is found in the specification and claims as filed. Accordingly, the amendments do not constitute the addition of new matter.

Applicants would like to initially thank Examiner Rawlings for the courteous interview extended to Applicants' representatives, Daniel Altman and Connie Tong, on May 12, 2005. Applicants have amended the claims along the lines discussed during the interview. On the basis of the interview, and in response to the Office Action mailed December 7, 2004, Applicants respectfully request the Examiner to reconsider the above-captioned application in view of the foregoing amendments and the following comments.

#### Objection of the Specification

The substitute specification sent with the previous Amendment was not entered because the marked-up copy of the substitute specification failed to show each and every change made relative to the immediate version of the specification. The present objections to the specification are the result of the non-entry of the substitute specification of July 30, 2004.

The specification has been amended to include the changes already made to the originally filed specification by the amendment filed November 6, 2003. The present amendments to the specification are made in response to the objections to the specification as outlined in the present Office Action and to reflect amended sequence identifiers. These amendments include amending the Abstract to be one paragraph; insertion of sequence identifiers; demarcation of trademarked terms; and, correction of various misspellings. Additionally, the misspelling in Figure 2 has been corrected in response to the drawing objection. No new matter has been added.

Accordingly, Applicants respectfully request the Examiner to reconsider and enter the present substitute specification.

Appl. No. : 09/581,651  
Filed : October 10, 2000

#### Objection to Claims

The Examiner objected to Claim 2 because of a mismatched sequence. The mismatched sequence has been corrected. A replacement sequence listing reflects the corrected SEQ ID NO:2, which corresponds to the sequence in Figure 2. Also, the sequence in Figure 2 is now correctly labeled "pMSF-1 $\alpha$ ."

The Examiner objected to Claim 27 for a misspelling of "SEQ ID NO." Claim 27 has been cancelled without prejudice.

The Examiner objected to Claim 29 because of improper Markush claim language. Claim 29 has been amended to correct the Markush claim language.

Accordingly, Applicants respectfully request the Examiner to reconsider and withdraw the claim objections.

#### Rejection under 35 U.S.C. § 101

The Examiner rejected Claim 8 under 35 U.S.C. § 101 because the Examiner believes that the claimed invention is directed to non-statutory subject matter. Claim 8 has been amended to recite "isolated" before "host cell," as suggested by the Examiner.

Accordingly, Applicants respectfully request the Examiner to reconsider and withdraw the rejection under 35 U.S.C. § 101.

#### Rejection under 35 U.S.C. § 112, first paragraph

The Examiner rejected Claims 1-3, 6-13, 27, 29, 56, 57, and 59 under 35 U.S.C. § 112, first paragraph, as failing to comply with either the written description requirement or the enablement requirement. The Examiner is objecting to the terms "variants thereof," "fragments thereof," and "derivatives." The Examiner believes that these terms describe an abundance of different proteins, which differ in structure and function. Claim 1 has been amended to remove reference to the variants, fragments, and derivatives. The specification describes a number of utilities for the polynucleotide recited in Claim 1. For example, the polynucleotide can encode a polypeptide having MSF activity (See page 46 of the substitute

Appl. No. : 09/581,651  
Filed : October 10, 2000

specification). It can also encode a protein that can be used to raise antibodies unique to the MSF tail (see page 46 of the substitute specification) and to hybridize to a gene that encodes MSF activity, such as to obtain information regarding the MSF gene by using PCR reactions (see page 47 of the substitute specification).

Claim 10 has been amended to recite "[a] polypeptide encoded by the polynucleotide having SEQ ID NO: 4," as suggested by the Examiner during the interview. This amendment also removes reference to various fragments and derivatives, thereby overcoming the rejection.

The Examiner rejected Claims 6, 13, and 59 under 35 U.S.C. § 112, first paragraph, for written description and under 35 U.S.C. § 112, second paragraph, for the term "migration stimulation factor activity." These claims have now been cancelled, rendering the rejection moot.

Accordingly, Applicants respectfully request the Examiner to reconsider and withdraw the rejections under 35 U.S.C. § 112, first paragraph.

#### Rejection under § 102-Grey and Schor

The Examiner rejected Claims 10-13, 27, 29, 56, 57, and 59 under 35 U.S.C. § 102(b) as being anticipated by Grey et al. (*PNAS* 1989 Apr; 86: 2438-2442), as evidenced by Schor et al. (*Cancer Res* 2003 Dec; (24): 8827-8836).

Grey et al. describes the purification of the migration stimulating factor produced by fetal and cancer patient fibroblasts, but no amino acid sequence information is given. Although the Schor et al. reference is not prior art, the Examiner uses the reference to show that the polypeptide in the Grey et al. reference inherently has the recited sequence. However, in order to inherently anticipate, there must be "a basis in fact and/or technical reasoning to reasonably support the determination that the allegedly inherent characteristic necessarily flows from the teachings of the applied prior art." M.P.E.P. 2112, (emphasis in original citation). "The fact that a certain result or characteristic may occur or be present in the prior art is not sufficient to establish the inherency of that result or characteristic." *Id.*

Appl. No. : 09/581,651  
Filed : October 10, 2000

In the present case, no evidence is present that the Grey et al. reference necessarily discloses a protein having the recited sequence. Grey et al. does not say which portion of the protein is obtained. Nor does it disclose the sequence of the portion that was obtained. We now know that there are at least two forms of MSF. The present specification discloses that there is a 642-amino acid form. Schor et al. discloses a 657-amino acid form. Attached, as an appendix, is the entry for European Molecular Biology Laboratory accession number AJ535086, the sequence for the full length cDNA cloned in the Schor et al. reference; see page 8829, results section. The translation of the cDNA is shown in the entry and is different from the claimed sequences. The protein translation of the cDNA of accession number AJ535086 shows a 657-residue protein. The sequence as shown in Figure 2 contains 642 residues. The sequence as shown in Figure 2 does not contain a 15-residue portion that is present in accession number AJ535086.

Thus, the sequence in Figure 2 is not the same as the sequence in Schor et al. There is no way to know whether the peptide in Grey et al. has the same sequence as the one disclosed in the present application. There is no sequence information or any other identifying information about the sequence in Grey et al that would lead one in the art to conclude that the Grey et al. peptide is the same as the peptide disclosed in the present application. Accordingly, Claim 10, which recites a sequence based on Figure 2, must be considered novel over Grey et al.

Claim 10 has been amended to recite "[a] polypeptide encoded by the polynucleotide having SEQ ID NO: 4." Claim 5, which is directed to the polynucleotide having SEQ ID NO: 4, has been found allowable. Accordingly, a polypeptide based on the polynucleotide having SEQ ID NO: 4 should also be allowable. Essentially, a polypeptide is a product of the translation process. Therefore, a translation of the patentable polynucleotide having SEQ ID NO: 4 should also provide for a patentable polypeptide sequence.

The features of Claims 29 and 56 are not inherent in Grey et al. Claim 29 is directed to specific fragments found in MSF. Claim 56 is directed to a pharmaceutical composition comprising a polypeptide of Claim 10, which is based on SEQ ID NO:4.

Appl. No. : 09/581,651  
Filed : October 10, 2000

Accordingly, Applicants respectfully request the Examiner to reconsider and withdraw the rejection under 35 U.S.C. § 102(b) with respect to Grey and Schor.

Rejection under § 102-WO 94/16085 A2

The Examiner rejected Claims 1-3, 6-13, 27, 56, and 59 under 35 U.S.C. § 102(b) as being anticipated by WO 94/16085 A2. According to the Examiner, WO 94/16085 A2 discloses a polypeptide comprising a variant of SEQ ID NO:1.

According to M.P.E.P. 2131.01, "a claim is anticipated only if each and every element as set forth in the claims is found, in either expressly or inherently described, in a single prior art reference."

Claim 1 has been amended to recite "A recombinant polynucleotide encoding a polypeptide comprising the amino acid sequence VSIPPRNLGY (SEQ ID NO: 41): wherein the polypeptide has migration stimulation factor activity; and wherein migration stimulation factor activity refers to stimulation of adult skin fibroblast migration."

VSIPPRNLGY (SEQ ID NO: 41) is unique to MSF. See Example 3 on page 46 of the specification. WO 94/16085 A2 relates to polypeptides that comprise sequences derived from fibronectin. WO 94/16085 A2 does not disclose a polypeptide comprising a variant of SEQ ID NO:41.

Accordingly, Applicants respectfully request the Examiner to reconsider and withdraw the rejection under 35 U.S.C. § 102(b) with respect to WO 94/16085 A2.

Rejection under § 102-Bristow and Benoliel

The Examiner rejected Claims 12, 56, 57, and 59 under 35 U.S.C. § 102 (b) as being anticipated by Bristow (*Trends Biotechnol.* 1993 Jul; 11 (7): 301-305), as evidenced by Benoliel et al. (*J. Cell Sci.* 1997 Sep; 110 (pt 17):2089-2097. Bristow et al. discloses recombinant-DNA-derived insulin analogues as potentially useful therapeutic agents. Benoliel et al. discloses that insulin stimulates haptotactic migration of human epidermal keratinocytes through activation of NF-κB transcription factor.

Appl. No. : 09/581,651  
Filed : October 10, 2000

According to the Examiner, Claims 12, 56, 57, and 59 read on any polypeptide that could be produced by a process comprising culturing a host cell according to Claim 8.

Claims 12, 57, and 59 have been cancelled without prejudice.

Claim 56 has been amended to be an independent claim and recites: "[a] pharmaceutical composition comprising a polypeptide according to Claim 10 and a pharmaceutically acceptable carrier." Claim 10 recites a polypeptide encoded by the polynucleotide having SEQ ID NO:4.

Nothing in the prior art discloses or suggests either the polypeptide encoded by a polynucleotide having SEQ ID NO:4 or the inclusion of such a polypeptide in a pharmaceutically acceptable carrier.

Accordingly, Applicants respectfully request the Examiner to reconsider and withdraw the rejection under 35 U.S.C. § 102(b) with respect to Bristow and Benoliel.

#### Rejections under § 103

The Examiner rejected Claims 1-3 and 6-9 under 35 U.S.C. § 103(a) as being unpatentable over Grey et al. (*PNAS* 1989Apr; 86: 2438-2442), as evidenced by Schor et al. (*Cancer Res.* 2003 Dec; 63 (24): 8827-8836), in view of Bendig (*Genet. Eng.* 1988; (7): 91-127).

As stated above, Grey et al. describes the purification of the migration stimulating factor produced by fetal and cancer patient fibroblasts, but no amino acid sequence information is given. Grey et al. utilized fibroblast cell lines from foreskin, fetal limb dermal fibroblasts, and forearm dermal fibroblasts from cancer patient. Although the Schor et al. reference is not prior art, the Examiner uses the reference to show that the polypeptide in the Grey et al. reference inherently has the recited sequence. Schor et al. utilizes a human fetal lung fibroblast cell line. Accordingly, Schor et al. uses a different source for characterization of the polypeptide than Grey et al.

Attached, as an appendix, is the entry for European Molecular Biology Laboratory accession number AJ535086, the sequence for the full length cDNA cloned in the Schor et al. reference; see page 8829, results section. The translation of the cDNA is shown in the entry

Appl. No. : 09/581,651  
Filed : October 10, 2000

and is different from the claimed sequences. The protein translation of the cDNA of accession number AJ535086 shows a 657-residue protein. The sequence as shown in Figure 2, contains 642 residues. The sequence as shown in Figure 2 also does not contain a 15-residue portion that is present in accession number AJ535086. Accordingly, the sequence as shown in Figure 2 is different from the sequence in Schor et al.

Claim 1 has been amended to recite "A recombinant polynucleotide encoding a polypeptide comprising the amino acid sequence VSIPPRNLGY (SEQ ID NO: 41): wherein the polypeptide has migration stimulation factor activity; and wherein migration stimulation factor activity refers to stimulation of adult skin fibroblast migration." SEQ ID NO:41 comprises a unique tail of MSF.

Grey et al. does not teach or suggest a recombinant polynucleotide encoding a polypeptide comprising the amino acid sequence (SEQ ID NO: 41). Grey et al. does not provide any polynucleotide or polypeptide sequences. While the Examiner uses the non-prior art Schor et al. reference to show that the polypeptide in the Grey et al. reference inherently has the recited sequence, Schor et al. utilizes a different source as Grey et al. to obtain the polypeptide. Schor et al. does not prove what Grey et al. obtained. Even if Schor et al. did prove so, the polynucleotide sequence is not suggestive. Accordingly, the polypeptide in Schor et al. is not necessarily representative of the polypeptide in Grey et al.

Moreover, according to M.P.E.P. 2144.09, "the existence of a general method of isolating cDNA or DNA molecules is essentially irrelevant to the question whether the specific molecules themselves would have been obvious, in the absence of other prior art that suggests the claimed DNAs." See *In re Deuel*, 51 F.3d 1552, 1558, 34 USPQ2d 1210, 1215 (Fed. Cir. 1995). There is no prior art cited that specifically suggest the claimed DNA. Therefore, the use of the Bendig reference is irrelevant to the present rejection.

Accordingly, Applicants respectfully request the Examiner to reconsider and withdraw the rejection under 35 U.S.C. § 103(a).



Appl. No. : 09/581,651  
Filed : October 10, 2000

Rejoinder

According to M.P.E.P. 821.04, where product and process claims drawn to independent and distinct inventions are presented in the same application, applicant may be called upon under 35 U.S.C. § 121 to elect claims to either the product or process. The claims to the nonelected invention will be withdrawn from further consideration under 37 C.F.R. § 1.142. However, if applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims which depend from or otherwise include all the limitations of the allowable product claim will be rejoined. Accordingly, upon allowance of Claims 1 and/or 10, the Applicants request rejoinder of Claims 36-42, 44, 47-51, 53, and 58, in accordance with M.P.E.P. 821.04.

Replacement Sequence Listing

Enclosed herewith are (1) a paper copy of the Replacement Sequence Listing, and (2) a computer-readable version of the Replacement Sequence Listing. This Amendment directs entry of the paper copy of the Listing into the application. No new matter is being added herewith.

Verification under 37 C.F.R. § 1.821(f) & (g)

All of the sequences in the attached Sequence Listing were included in the application as filed. Pursuant to 37 C.F.R. § 1.821(g), no new matter is being added herewith. As required under 37 C.F.R. § 1.821(f), I hereby verify that the data on the enclosed disk and the paper copies of the Sequence Listing are identical.

CONCLUSION

In view of the foregoing amendments and comments, it is respectfully submitted that the present application is fully in condition for allowance, and such action is earnestly solicited.


Appl. No. : 09/581,651  
Filed : October 10, 2000

The undersigned has made a good faith effort to respond to all of the rejections in the case and to place the claims in condition for immediate allowance. Nevertheless, if any undeveloped issues remain or if any issues require clarification, the Examiner is respectfully invited to call the undersigned in order to resolve such issue promptly.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 3, 2005

By:   
Connie C. Tong  
Registration No. 52,292  
Agent of Record  
Customer No. 20,995  
(949) 760-0404

1532006\_1:cb 060205



European Bioinformatics Institute

Get Nucleotide sequences for  Go ? Site search



EBI Home

About EBI

Research


Services

Toolbox

Databases

Downloads

DATABASE BROWSING



## EBI Dbfetch

```
ID  HSAS35086  standard; mRNA; HUM; 2192 BP.
XX
AC  AJ535086;
XX
SV  AJ535086.1
XX
DT  17-DEC-2002 (Rel. 74, Created)
DT  17-DEC-2002 (Rel. 74, Last updated, Version 1)
XX
DE  Homo sapiens mRNA for migration stimulation factor FN70+ (FN gene)
XX
KW  FN gene; migration stimulation factor FN70+.
XX
OS  Homo sapiens (human)
OC  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC  Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo.
XX
RN  [1]
RP  1-2192
RA  Schor S.L.;
RT  ;
RL  Submitted (13-DEC-2002) to the EMBL/GenBank/DDBJ databases.
RL  Schor S.L., University of Dundee, The Dental School, Park Place, Dundee,
RL  DD1 4HR, UNITED KINGDOM.
XX
RN  [2]
RA  Schor S.L., Schor A.M., Kay R.A.;
RT  "The sequence of MSF/FN70 + variant";
RL  Unpublished.
XX
FH  Key          Location/Qualifiers
FH
FT  source        1..2192
FT                /db_xref="taxon:9606"
FT                /mol_type="mRNA"
FT                /organism="Homo sapiens"
FT  5'UTR         1..56
FT                /gene="FN"
FT  CDS           57..2030
FT                /db_xref="GOA:P02751"
FT                /db_xref="Genew:3778"
FT                /db_xref="HSSP:Q96KP7"
FT                /db_xref="UniProt/Swiss-Prot:P02751"
FT                /gene="FN"
FT                /product="migration stimulation factor FN70+"
FT                /protein_id="CAD59389.1"
FT                /translation="MLRGGPGGLLLAVQCLGTAVPSTGASKSKRQAQQMVQPQSPVAV
FT                SQSKPGCYDNGKHYQINQWERTYLGNALVCTCYGSGRGFNCESKPEAEETCFDKYTGN
FT                TYRVGDTYERPKDSMIWDCTCIGAGRGRISCTIANRCHEGGQSYKIGDTWRRPHETGGY
FT                MLECVCLGNGKGEWTKPIAEKCFDHAAGTSYVVGETWEKPYQGWMVVDCTCLGEGSGR
FT                ITCTSRNRCNDQDTRTSYRIGDTWRKKDNRGNLLQCICTGNRGGEWK CERHTSVQTTSS
FT                GSGPFTDVRAAVYQPQPHPPPYGHCVTDSGVVYSGVMQWLKTQGNKQMLCTCLGNGV
FT                SCQETAVTQTYGGSNGEPCVLPFTYNGRTFYSCCTTEGRQDGHLCSTTSNYEQDQKYS
```

FT FCTDHTVLVQTRGGNSNGALCHFPFLYNNHNYTDCTSEGRDNDNMKWCCTTQNYDADQKF  
 FT GFCPMAAHEEICTTNEGVMYRIGDQWDKQHDMMRCTCVGNRGGEWTCIAYSQLRDQ  
 FT CIVDDITYNVNDTFHKRHEEGHMLNCTCFGQGRGRWKCDPVDQCQDSETGTIFYQIGDSW  
 FT EKYPVHGVRYQCYCYGRGIGEWHCQPLQTYPSSSGPVEVFITETPSQPNSHPIQWNAPQP  
 FT SHISKYILRWRPVSIPPRNLGY"  
 FT 3'UTR 2031..2192  
 FT /gene="FN"  
 XX  
 SQ

Sequence 2192 BP; 583 A; 525 C; 588 G; 496 T; 0 other;  
 caaacttggg ggcaacttgc ctcccgggtc gggcggtctc cccccaccgt ctcaacatgc 60  
 ttaggggtcc ggggcccggg ctgctgctgc tggccgtcca gtgcctgggg acagcgggtc 120  
 cctccacggg agcctcgaag agcaagaggc aggcctcagca aatgggtcag cccagtcgcc 180  
 cgggtggctgt cagtcaaagc aagcccgttt gttatgacaa tggaaaaacac tatcagataa 240  
 atcaacagtg ggagcggacc tacctaggca atgcgttggg ttgtacttgt tatggaggaa 300  
 gccgaggttt taactgcgag agtaaacctg aagctgaaga gacttgcttt gacaagtaca 360  
 ctgggaacac ttaccgagtg ggtgacactt atgagcgctc taaagactcc atgatctggg 420  
 actgtacctg catcggggct gggcgaggga gaataagctg taccatcgca aaccgctgcc 480  
 atgaaggggg tcagtcctac aagattgggtg acacctggag gagaccacat gagactgggtg 540  
 gttacatggt agagtgtgtg tgtcttggta atggaaaagg agaatggacc tgcaagccca 600  
 tagctgagaa gtgttttgat catgctgctg ggacttccta tgtggtcggg gaaacgtggg 660  
 agaagcccta ccaaggtctg atgatggtag attgtacttg cctgggagaa ggcagcggac 720  
 gcatcacttg cacttctaga aatagatgca acgatcagga cacaaggaca tcctatagaa 780  
 ttggagacac ctggcgcaag aaggataatc gaggaacctt gctccagtgc atctgcacag 840  
 gcaacggccg aggagagtgg aagtgtgaga ggcacacctc tgtgcagacc acatcgagcg 900  
 gatctggccc cttcaccgat gttcgtgcag ctgtttacca accgcagcct cacccccagc 960  
 ctctcccta tggccactgt gtcacagaca gtggtgtggg ctactctgtg gggatgcagt 1020  
 ggctgaagac acaaggaaat aagcaaatgc ttgacacgtg cctgggcaac ggagtcagct 1080  
 gccaagagac agctgtaacc cagacttacg gtggcaactc aaatggagag ccatgtgtct 1140  
 taccattcac ctacaatggc aggacgttct actcctgcac cacagaaggg cgacaggacg 1200  
 gacatctttg gtgcagcaca acttcgaatt atgagcagga ccagaaatac tctttctgca 1260  
 cagaccacac tgttttgggt cagactcgag gaggaaattc caatggtgcc ttgtgccact 1320  
 tccccttcct atacaacaac cacaattaca ctgattgcac ttctgagggc agaagagaca 1380  
 acatgaagtg gtgtgggacc acacagaact atgatgccga ccagaagttt gggttctgcc 1440  
 ccatggctgc ccacgaggaa atctgcacaa ccaatgaagg ggtcatgtac cgcattggag 1500  
 atcagtggga taagcagcat gacatgggtc acatgatgag gtgcacgtgt gttgggaatg 1560  
 gtcgtgggga atggacatgc attgcctact cgcagcttcg agatcagtg atgttgatg 1620  
 acatcactta caatgtgaac gacacattcc acaagcgta tgaagagggg cacatgctga 1680  
 actgtacatg cttcgggtcag ggtcggggca ggtggaaagt tgatcccgtc gaccaatgcc 1740  
 aggattcaga gactgggacg ttttatcaaa ttggagattc atgggagaa tatgtgcatg 1800  
 gtgtcagata ccagtgtctc tgctatggcc gtggcattgg ggagtggcat tgccaacctt 1860  
 tacagacctc tccaagctca agtggtcctg tcgaagtatt tatcactgag actccgagtc 1920  
 agcccaactc ccaccccatc cagtggaatg caccacagcc atctcacatt tccaagtaca 1980  
 ttctcaggtg gagacctgtg agtatccac ccagaaacct tggatactga gtctcctaata 2040  
 cttatcaatt ctgatgggtt ctttttttcc cagcttttga gccaaacaact ctgattaact 2100  
 attcctatag catttactat atttgtttag tgaacaaaca atatgtgggtc aattaaattg 2160  
 acttgtagac tgaaaaaaaa aaaaaaaaaa aa 2192

//



## POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF

The sequence listing is hereby incorporated by reference in its entirety. The sequence listing (35001372.txt) is saved on two (2) floppy discs in computer readable for (CRF) and is hereby incorporated by reference in its entirety.  
5 The paper copy of the sequence listing and the CRF copy found on two (2) floppy discs are identical. That is the sequence listing was printed from the file in CRF format found on the floppy discs.

10 The present invention relates to polypeptides, polynucleotides and uses thereof and in particular to migration stimulating factor (MSF).

MSF has been described previously in the following papers. Schor *et al* (1988) *J. Cell Sci.* 90: 391-399 shows that foetal and cancer patient  
15 fibroblasts produce an autocrine migration stimulating factor not made by normal adult cells. Schor *et al* (1988) *J. Cell Sci.* 90: 401-407, shows that fibroblasts from cancer patients display a mixture of both foetal and adult phenotypic characteristics. Schor *et al* (1989) *In Vitro* 25: 737-746 describes a mechanism of action of the migration stimulating factor (MSF)  
20 produced by fetal and cancer patient fibroblasts and its effect on hyaluronic acid synthesis. Grey *et al* (1989) *Proc. Natl. Acad. Sci. (USA)* 86: 2438-2442 describes the purification of the migration stimulating factor produced by fetal and cancer patient fibroblasts but no amino acid sequence information is given. It is suggested that MSF has a molecular weight of  
25 70kDa. Schor & Schor (1990) *Cancer Investig.* 8: 665-667 describes the characterisation of migration stimulating activity (MSF) and gives evidence for its role in cancer pathogenesis. Picardo *et al* (1991) *Lancet* 337: 130-133 describes the presence of migration stimulating activity in the serum of breast cancer patients. Ellis *et al* (1992) *J. Cell Sci.* 102: 447-456 describes

the antagonistic effects of transforming growth factor- $\beta$ 1 and MSF on fibroblast migration and hyaluronic acid synthesis and discusses the possible implications for wound healing. Picardo *et al* (1992) *Exp. Mol. Path.* 57: 8-21, describes the identification of migration stimulating factor in wound fluid. Irwin *et al* (1994) *J. Cell Sci.* 107: 1333-1346, describes the inter- and intra-site heterogeneity in the expression of fetal-like phenotypic characteristics by gingival fibroblasts and discusses the potential significance for wound healing. Schor *et al* (1994) *Int J Cancer.* 59: 25-32 describes the phenotypic heterogeneity in breast fibroblasts and discusses functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. Schor *et al* (1991) In: *Cell Motility Factors* (ed. I Goldberg) pp. 127-146, Birkhauser Press, Basel, describes the heterogeneity amongst fibroblasts in the production of migration stimulating factor (MSF) and discusses implications for cancer pathogenesis. Schor *et al* (1993) In: *Cell behaviour: Adhesion and Motility.* (ed. G. Evans, C. Wigley and R. Warn) Society for Experimental Biology Symposium No. 47, pp. 234-251, describes the potential structural homology of MSF to the gelatin-binding domain of fibronectin its potential mode of action and possible function in health and disease. A small amount of partial amino acid sequence is given, but this sequence is similar to fibronectin and, in fact, is not present in the MSF which has now been cloned and sequenced in the present work (see below). It is suggested that MSF activity isolated from foetal fibroblast conditioned medium consists of three proteins, one with an apparent molecular weight of 119kDa and a double of 43 and 33kDa, and, indeed, it was suggested that MSF could be a proteolytic degradation product of fibronectin. Schor (1995) In: *Epithelial Mesenchymal Interactions in Cancer* (eg. I Goldberg and E Rosen). pp. 273-296. Birkhauser Press, Basel, describes fibroblast subpopulations as accelerators of tumor progression and the potential role of migration stimulating factor. MSF is

also discussed in Schor *et al* (1994) In: Mammary Tumorigenesis and Malignant Progression, Kluwer Academic Publishers, Dickson, R. and Lippman, M. (eds).

5 Thus, MSF is believed to be produced by fibroblasts obtained from a majority of breast cancer patients and is not made by their normal adult counterparts. It is believed that measuring the levels of MSF, for example, in circulating blood or in serum or in urine, may be useful in identifying patients who have or are susceptible to cancer, or that it may be useful in  
10 prognosing the outcome of cancer. MSF producing fibroblasts are present in patients with a number of common epithelial tumours, such as carcinoma of the breast, lung and colon, as well as melanoma, and soft tissue sarcoma.

It is believed that it may be particularly useful to measure the levels of MSF  
15 in identifying patients who have or are susceptible to breast cancer, or in prognosing the outcome of breast cancer.

In addition, it is believed that MSF may be useful in wound healing since it is present in a majority of wound fluid samples. The directed migration of  
20 fibroblasts into the wound site and the transient increase in hyaluronic acid in granulation tissue during the wound healing response are both consistent with the involvement of MSF. (MSF stimulates the synthesis of a high molecular weight species of hyaluronic acid).

25 MSF is known to be related to fibronectin since certain antibodies raised to MSF also bind to fibronectin.

Fibronectin is a widely distributed glycoprotein present at high concentrations in most extracellular matrices, in plasma (300 µg/ml), and in

other body fluids. Fibronectin is a prominent adhesive protein and mediates various aspects of cellular interactions with extracellular matrices including migration. Its principal functions appear to be in cellular migration during development and wound healing, regulation of cell growth and  
5 differentiation, and haemostasis/thrombosis.

Further progress in understanding MSF was hindered by the fact that it has not been clear whether MSF is a degradation or breakdown product of fibronectin, and because MSF appears to be structurally related to  
10 fibronectin.

We have now discovered that MSF is not a breakdown product of fibronectin but that it appears, quite unexpectedly, to be a "mini" splice variant of fibronectin. The amino acid sequence of MSF, disclosed for the  
15 first time herein, reveals unexpected regions of dissimilarity with fibronectin. This has led to previously unavailable methods of measuring, identifying and localising MSF becoming available. The availability of a polynucleotide encoding MSF, disclosed for the first time herein, makes available methods for producing MSF and useful variants thereof, and  
20 makes available new methods of specifically identifying, measuring and localising MSF.

A first aspect of the invention provides a recombinant polynucleotide encoding a polypeptide comprising the amino acid sequence

25

N L V A T C L P V R A S L P H R L N  
M L R G P G P G L L L A V Q C L G T A V P S T G A S K S K  
R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
30 P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
35 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C



5 E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
 10 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 15 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y  
 (SEQ ID NO: 1)

15 or variants or fragments or fusions or derivatives thereof, or fusions of said  
 variants or fragments or derivatives.

Figure 2 shows the amino acid sequence encoded by the cDNA insert in  
 pMSF1I which contains the coding sequence for human migration  
 20 stimulating factor (MSF). Preferably the amino acid sequence is based on  
 that between the most N-terminal methionine and the most C-terminal stop  
 codon (which are marked X). Thus, it is preferred if the polynucleotide  
 encodes a polypeptide comprising the amino acid sequence shown in Figure  
 2 labelled pMSF1I between positions 19 and 660 (SEQ ID NO: 2) (ie.  
 25 starting MLRGPG... as marked and encoding ...LGY as marked), or variants  
 of fragments or fusions or derivatives thereof or fusions of said variants or  
 fragments.

Throughout the specification where the term MSF is used, and the context  
 30 does not indicate otherwise, it includes a polypeptide which has an amino  
 acid sequence given in Figure 2 labelled pMSF1I and, in particular, the  
 amino acid sequence given between positions 19 and 660 (SEQ ID NO: 2).

Amino acid residues are given in standard single letter code or standard  
 35 three letter code throughout the specification.

It will be appreciated that the recombinant polynucleotides of the invention are not polynucleotides which encode fibronectin or fragments of fibronectin such as the gelatin binding domain. Preferably, the fragments and variants and derivatives are those that include a polynucleotide which  
5 encodes a portion or portions of MSF which are portions that distinguish MSF from fibronectin and which are described in more detail below and by reference to Figure 2.

The polynucleotide may be DNA or RNA but it is preferred if it is DNA.  
10 The polynucleotide may or may not contain introns. It is preferred that it does not contain introns and it is particularly preferred if the polynucleotide is a cDNA.

A polynucleotide of the invention is one which comprises the polynucleotide  
15 whose sequence is given in Figure 1. Thus, a polynucleotide of the invention includes the sequence

```
CAAACCTTGGT GGCAACTTGC CTCCCGGTGC GGGCGTCTCT CCCCCACCGT
CTCAACATGC TTAGGGGTCC GGGGCCCGGG CTGCTGCTGC TGGCCGTCCA
20 GTGCCTGGGG ACAGCGGTGC CCTCCACGGG AGCCTCGAAG AGCAAGAGGC
AGGCTCAGCA AATGGTTCAG CCCAGTCCC CCGTGGCTGT CAGTCAAAGC
AAGCCCGGTT GTTATGACAA TGGAAAACAC TATCAGATAA ATCAACAGTG
GGAGCGGACC TACCTAGGCA ATGCGTTGGT TTGTACTTGT TATGGAGGAA
GCCGAGGTTT TAACTGCGAG AGTAAACCTG AAGCTGAAGA GACTTGCTTT
25 GACAAGTACA CTGGGAACAC TTACCGAGTG GGTGACACTT ATGAGCGTCC
TAAAGACTCC ATGATCTGGG ACTGTACCTG CATCGGGGCT GGGCGAGGGA
GAATAAGCTG TACCATCGCA AACCGCTGCC ATGAAGGGGG TCAGTCCTAC
AAGATTGGTG ACACCTGGAG GAGACCACAT GAGACTGGTG GTTACATGTT
AGAGTGTGTG TGTCTTGGTA ATGGAAAAGG AGAATGGACC TGCAAGCCCA
30 TAGCTGAGAA GTGTTTTGAT CATGCTGCTG GGACTTCCTA TGTGGTCGGA
GAAACGTGGG AGAAGCCCTA CCAAGGCTGG ATGATGGTAG ATTGTACTTG
CCTGGGAGAA GGCAGCGGAC GCATCACTTG CACTTCTAGA AATAGATGCA
ACGATCAGGA CACAAGGACA TCCTATAGAA TTGGAGACAC CTGGAGCAAG
AAGGATAATC GAGGAAACCT GCTCCAGTGC ATCTGCACAG GCAACGGCCG
35 AGGAGAGTGG AAGTGTGAGA GGCACACCTC TGTGCAGACC ACATCGAGCG
GATCTGGCCC CTTACCCGAT GTTCGTGCAG CTGTTTACCA ACCGCAGCCT
CACCCCAGC CTCCTCCCTA TGGCCACTGT GTCACAGACA GTGGTGTGGT
CTACTCTGTG GGGATGCAGT GGCTGAAGAC ACAAGGAAAT AAGCAAATGC
TTTGACAGTG CTTGGGCAAC GGAGTCAGCT GCCAAGAGAC AGCTGTAACC
40 CAGACTTACG GTGGCAACTC AAATGGAGAG CCATGTGTCT TACCATTAC
CTACAACGAC AGGACGGACA GCACAACCTC GAATTATGAG CAGGACCAGA
AATACTCTTT CTGCACAGAC CACACTGTTT TGGTTCAGAC TCGAGGAGGA
AATTCCAATG GTGCCTTGTG CCACTTCCCC TTCCTATACA ACAACCACAA
TTACACTGAT TGCATTCTG AGGGCAGAAG AGACAACATG AAGTGGTGTG
45 GGACCACACA GAACTATGAT GCCGACCAGA AGTTTGGGTT CTGCCCCATG
```

5 GCTGCCCCAG AGGAAATCTG CACAACCAAT GAAGGGGTCA TGTACCGCAT  
 TGGAGATCAG TGGGATAAGC AGCATGACAT GGGTCACATG ATGAGGTGCA  
 CGTGTGTTGG GAATGGTCGT GGGGAATGGA CATGCATTGC CTACTCGCAG  
 CTTTCGAGATC AGTGCATTGT TGATGACATC ACTTACAATG TGAACGACAC  
 10 ATTCCACAAG CGTCATGAAG AGGGGCACAT GCTGAACTGT ACATGCTTCG  
 GTCAGGGTCG GGGCAGGTGG AAGTGTGATC CCGTCGACCA ATGCCAGGAT  
 TCAGAGACTG GGACGTTTTA TCAAATTGGA GATTCATGGG AGAAGTATGT  
 GCATGGTGTC AGATAACAGT GCTACTGCTA TGGCCGTGGC ATTGGGGAGT  
 GGCATTGCCA ACCTTTACAG ACCTATCCAA GCTCAAGTGG TCCTGTCGAA  
 15 GTATTTATCA CTGAGACTCC GAGTCAGCCC AACTCCCACC CCATCCAGTG  
 GAATGCACCA CAGCCATCTC ACATTTCCAA GTACATTCTC AGGTGGAGAC  
 CTGTGAGTAT CCCACCCAGA AACCTTGGAT ACTGAGTCTC CTAATCTTAT  
 CAATTCTGAT GGTTCTTTT TTCCAGCT TTTGAGCCAA CAACTCTGAT  
 TAACTATTC TATAGCATTT ACTATATTG TTTAGTGAAC AAACAATATG  
 20 TGGTCAATTA AATTGACTTG TAGACTGAAA AAAAAAAAAA AAAAAAA  
 (SEQ ID NO: 23)

It is particularly preferred if the polynucleotide of the invention is one which  
 comprises the polynucleotide whose sequence is given between positions 57  
 20 and 1982 (SEQ ID NO: 4) in Figure 1 since this is believed to be the coding  
 sequence for human MSF.

The invention includes a polynucleotide comprising a fragment of the  
 recombinant polynucleotide of the first aspect of the invention. Preferably,  
 25 the polynucleotide comprises a fragment which is at least 10 nucleotides in  
 length, more preferably at least 14 nucleotides in length and still more  
 preferably at least 18 nucleotides in length. Such polynucleotides are useful  
 as PCR primers.

30 A "variation" of the polynucleotide includes one which is (i) usable to  
 produce a protein or a fragment thereof which is in turn usable to prepare  
 antibodies which specifically bind to the protein encoded by the said  
 polynucleotide or (ii) an antisense sequence corresponding to the  
 polynucleotide or to a variation of type (i) as just defined. For example,  
 35 different codons can be substituted which code for the same amino acid(s)  
 as the original codons. Alternatively, the substitute codons may code for a  
 different amino acid that will not affect the activity or immunogenicity of  
 the protein or which may improve or otherwise modulate its activity or

immunogenicity. For example, site-directed mutagenesis or other techniques can be employed to create single or multiple mutations, such as replacements, insertions, deletions, and transpositions, as described in Botstein and Shortle, "Strategies and Applications of *In Vitro* Mutagenesis,"  
5 *Science*, 229: 193-210 (1985), which is incorporated herein by reference. Since such modified polynucleotides can be obtained by the application of known techniques to the teachings contained herein, such modified polynucleotides are within the scope of the claimed invention.

10 Moreover, it will be recognised by those skilled in the art that the polynucleotide sequence (or fragments thereof) of the invention can be used to obtain other polynucleotide sequences that hybridise with it under conditions of high stringency. Such polynucleotides includes any genomic DNA. Accordingly, the polynucleotide of the invention includes  
15 polynucleotide that shows at least 55 per cent, preferably 60 per cent, and more preferably at least 70 per cent and most preferably at least 90 per cent homology with the polynucleotide identified in the method of the invention, provided that such homologous polynucleotide encodes a polypeptide which is usable in at least some of the methods described below or is otherwise  
20 useful. It is particularly preferred that in this embodiment, the polynucleotide is one which encodes a polypeptide containing a portion or portions that distinguish MSF from fibronectin.

It is believed that MSF is found in mammals other than human. The present  
25 invention therefore includes polynucleotides which encode MSF from other mammalian species including rat, mouse, cow, pig, sheep, rabbit and so on.

Per cent homology can be determined by, for example, the GAP program of the University of Wisconsin Genetic Computer Group.

DNA-DNA, DNA-RNA and RNA-RNA hybridisation may be performed in aqueous solution containing between 0.1XSSC and 6XSSC and at temperatures of between 55 °C and 70 °C. It is well known in the art that the higher the temperature or the lower the SSC concentration the more stringent the hybridisation conditions. By "high stringency" we mean 2XSSC and 65 °C. 1XSSC is 0.15M NaCl/0.015M sodium citrate. Polynucleotides which hybridise at high stringency are included within the scope of the claimed invention.

10

"Variations" of the polynucleotide also include polynucleotide in which relatively short stretches (for example 20 to 50 nucleotides) have a high degree of homology (at least 80% and preferably at least 90 or 95%) with equivalent stretches of the polynucleotide of the invention even though the overall homology between the two polynucleotides may be much less. This is because important active or binding sites may be shared even when the general architecture of the protein is different.

By "variants" of the polypeptide we include insertions, deletions and substitutions, either conservative or non-conservative, where such changes do not substantially alter the activity of the said MSF.

Variants and variations of the polynucleotide and polypeptide include natural variants, including allelic variants and naturally-occurring mutant forms.

25

MSF may be assessed in bioassays based on its stimulation of adult skin fibroblast migration, for example, as is described in Picardo *et al* (1991) *The Lancet* 337, 130-133. Specificity for MSF may be inferred by neutralisation

of migration stimulating activity by anti-MSF polyclonal antibodies (as herein disclosed). MSF may also be assayed using immunological techniques such as ELISA and the like.

- 5 By "conservative substitutions" is intended combinations such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr.

Such variants may be made using the methods of protein engineering and site-directed mutagenesis well known in the art.

10

Preferably, the variant or variation of the polynucleotide encodes a MSF that has at least 30%, preferably at least 50% and more preferably at least 70% of the activity of a natural MSF, under the same assay conditions.

- 15 By "fragment of MSF" we include any fragment which retains activity or which is useful in some other way, for example, for use in raising antibodies or in a binding assay, but which is not a fragment of MSF which could also be a fragment of fibronectin.

- 20 By "fusion of MSF" we include said MSF fused to any other polypeptide. For example, the said protein kinase may be fused to a polypeptide such as glutathione-S-transferase (GST) or protein A in order to facilitate purification of MSF, or it may be fused to some other polypeptide which imparts some desirable characteristics on the MSF fusion. Fusions to any  
25 variant, fragment or derivative of MSF are also included in the scope of the invention.

A further aspect of the invention provides a replicable vector comprising a recombinant polynucleotide encoding MSF, or a variant, fragment,

derivative or fusion of MSF or a fusion of said variant, fragment or derivative.

A variety of methods have been developed to operably link polynucleotides, especially DNA, to vectors for example *via* complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.

10

Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. The DNA segment, generated by endonuclease restriction digestion as described earlier, is treated with bacteriophage T4 DNA polymerase or *E. coli* DNA polymerase I, enzymes that remove protruding, 3'-single-stranded termini with their 3'-5'-exonucleolytic activities, and fill in recessed 3'-ends with their polymerizing activities.

The combination of these activities therefore generates blunt-ended DNA segments. The blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase. Thus, the products of the reaction are DNA segments carrying polymeric linker sequences at their ends. These DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.

25

Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, CN, USA.

5 A desirable way to modify the DNA encoding the polypeptide of the invention is to use the polymerase chain reaction as disclosed by Saiki *et al* (1988) *Science* 239, 487-491. This method may be used for introducing the DNA into a suitable vector, for example by engineering in suitable restriction sites, or it may be used to modify the DNA in other useful ways  
10 as is known in the art.

In this method the DNA to be enzymatically amplified is flanked by two specific primers which themselves become incorporated into the amplified DNA. The said specific primers may contain restriction endonuclease  
15 recognition sites which can be used for cloning into expression vectors using methods known in the art.

The DNA (or in the case of retroviral vectors, RNA) is then expressed in a suitable host to produce a polypeptide comprising the compound of the  
20 invention. Thus, the DNA encoding the polypeptide constituting the compound of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of  
25 the invention. Such techniques include those disclosed in US Patent Nos. 4,440,859 issued 3 April 1984 to Rutter *et al*, 4,530,901 issued 23 July 1985 to Weissman, 4,582,800 issued 15 April 1986 to Crowl, 4,677,063 issued 30 June 1987 to Mark *et al*, 4,678,751 issued 7 July 1987 to Goeddel, 4,704,362 issued 3 November 1987 to Itakura *et al*, 4,710,463 issued 1



December 1987 to Murray, 4,757,006 issued 12 July 1988 to Toole, Jr. *et al*, 4,766,075 issued 23 August 1988 to Goeddel *et al* and 4,810,648 issued 7 March 1989 to Stalker, all of which are incorporated herein by reference.

- 5 The DNA (or in the case of retroviral vectors, RNA) encoding the polypeptide constituting the compound of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal  
10 maintenance or integration is desired.

Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational  
15 regulatory control nucleotide sequences recognised by the desired host, although such controls are generally available in the expression vector. The vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection  
20 technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance. Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.

25

Host cells that have been transformed by the recombinant DNA of the invention are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings

disclosed herein to permit the expression of the polypeptide, which can then be recovered.

Many expression systems are known, including bacteria (for example *E. coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*),  
5 filamentous fungi (for example *Aspergillus*), plant cells, animal cells and insect cells.

The vectors typically include a prokaryotic replicon, such as the ColE1 *ori*,  
10 for propagation in a prokaryote, even if the vector is to be used for expression in other, non-prokaryotic, cell types. The vectors can also include an appropriate promoter such as a prokaryotic promoter capable of directing the expression (transcription and translation) of the genes in a bacterial host cell, such as *E. coli*, transformed therewith.

15 A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with exemplary bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for  
20 insertion of a DNA segment of the present invention.

Typical prokaryotic vector plasmids are pUC18, pUC19, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA, USA) and pTrc99A and pKK223-3 available from Pharmacia, Piscataway, NJ, USA.

25 A typical mammalian cell vector plasmid is pSVL available from Pharmacia, Piscataway, NJ, USA. This vector uses the SV40 late promoter to drive expression of cloned genes, the highest level of expression being found in T antigen-producing cells, such as COS-1 cells.

An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. This vector uses the glucocorticoid-inducible promoter of the mouse mammary tumour virus long terminal repeat to drive  
5 expression of the cloned gene.

Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast  
10 Integrating plasmids (YIps) and incorporate the yeast selectable markers *HIS3*, *TRP1*, *LEU2* and *URA3*. Plasmids pRS413-416 are Yeast Centromere plasmids (Ycps).

Other vectors and expression systems are well known in the art for use with  
15 a variety of host cells.

The present invention also relates to a host cell transformed with a polynucleotide vector construct of the present invention. The host cell can be either prokaryotic or eukaryotic. Bacterial cells are preferred prokaryotic  
20 host cells and typically are a strain of *E. coli* such as, for example, the *E. coli* strains DH5 available from Bethesda Research Laboratories Inc., Bethesda, MD, USA, and RR1 available from the American Type Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343). Preferred eukaryotic host cells include yeast, insect and mammalian cells, preferably  
25 vertebrate cells such as those from a mouse, rat, monkey or human fibroblastic and kidney cell lines. Yeast host cells include YPH499, YPH500 and YPH501 which are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Preferred mammalian host cells include Chinese hamster ovary (CHO) cells available from the ATCC

as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, monkey kidney-derived COS-1 cells available from the ATCC as CRL 1650 and 293 cells which are human embryonic kidney cells. Preferred insect cells are Sf9 cells which can be transfected with  
5 baculovirus expression vectors.

Transformation of appropriate cell hosts with a DNA construct of the present invention is accomplished by well known methods that typically depend on the type of vector used. With regard to transformation of  
10 prokaryotic host cells, see, for example, Cohen *et al* (1972) *Proc. Natl. Acad. Sci. USA* **69**, 2110 and Sambrook *et al* (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Transformation of yeast cells is described in Sherman *et al* (1986) *Methods In Yeast Genetics, A Laboratory Manual*, Cold Spring Harbor, NY.  
15 The method of Beggs (1978) *Nature* **275**, 104-109 is also useful. With regard to vertebrate cells, reagents useful in transfecting such cells, for example calcium phosphate and DEAE-dextran or liposome formulations, are available from Stratagene Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA.

20

Electroporation is also useful for transforming and/or transfecting cells and is well known in the art for transforming yeast cell, bacterial cells, insect cells and vertebrate cells.

25 For example, many bacterial species may be transformed by the methods described in Luchansky *et al* (1988) *Mol. Microbiol.* **2**, 637-646 incorporated herein by reference. The greatest number of transformants is consistently recovered following electroporation of the DNA-cell mixture suspended in 2.5X PEB using 6250V per cm at 25°F.D.

Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente (1990) *Methods Enzymol.* **194**, 182.

- 5 Successfully transformed cells, ie cells that contain a DNA construct of the present invention, can be identified by well known techniques. For example, cells resulting from the introduction of an expression construct of the present invention can be grown to produce the polypeptide of the invention. Cells can be harvested and lysed and their DNA content  
10 examined for the presence of the DNA using a method such as that described by Southern (1975) *J. Mol. Biol.* **98**, 503 or Berent *et al* (1985) *Biotech.* **3**, 208. Alternatively, the presence of the protein in the supernatant can be detected using antibodies as described below.
- 15 In addition to directly assaying for the presence of recombinant DNA, successful transformation can be confirmed by well known immunological methods when the recombinant DNA is capable of directing the expression of the protein. For example, cells successfully transformed with an expression vector produce proteins displaying appropriate antigenicity.  
20 Samples of cells suspected of being transformed are harvested and assayed for the protein using suitable antibodies.

Thus, in addition to the transformed host cells themselves, the present invention also contemplates a culture of those cells, preferably a monoclonal  
25 (clonally homogeneous) culture, or a culture derived from a monoclonal culture, in a nutrient medium.

A further aspect of the invention provides a method of making MSF or a variant, derivative, fragment or fusion thereof or a fusion of a variant,

fragment or derivative, the method comprising culturing a host cell comprising a recombinant polynucleotide or a replicable vector which encodes said MSF or variant or fragment or derivative or fusion, and isolating said MSF or a variant, derivative, fragment or fusion thereof of a fusion or a variant, fragment or derivative from said host cell.

Methods of cultivating host cells and isolating recombinant proteins are well known in the art. It will be appreciated that, depending on the host cell, the MSF produced may differ from that which can be isolated from nature. For example, certain host cells, such as yeast or bacterial cells, either do not have, or have different, post-translational modification systems which may result in the production of forms of MSF which may be post-translationally modified in a different way to MSF isolated from nature. It is preferred if the host cell is a non-human host cell; more preferably it is not a mammalian cell.

It is preferred that recombinant MSF is produced in a eukaryotic system, such as an insect cell.

A further aspect of the invention provides MSF or a variant, fragment, derivative or fusion thereof or a fusion of a variant, fragment or derivative obtainable by the methods herein disclosed.

A further aspect of the invention provides a polypeptide comprising the amino acid sequence

N L V A T C L P V R A S L P H R L N  
M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K  
R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K

P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
 E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
 5 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 10 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 15 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

(SEQ ID NO: 1)

or variants or fragments or fusions or derivatives thereof or fusions of said  
variants or fragments or derivatives.

20

Thus, a polypeptide of the invention includes

N L V A T C L P V R A S L P H R L N  
 M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K  
 25 R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
 I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
 P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
 W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
 G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
 30 P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
 E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
 35 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 40 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 45 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

(SEQ ID NO: 1)

Preferably, the polypeptide comprises the amino acid sequence shown in  
 Figure 2 labelled pMSF1I between positions 19 and 660 (SEQ ID NO: 2), or  
 50 variants or fragments or fusions or derivatives thereof or fusions of said  
 variants or fragments or derivatives.

It will be appreciated that the polypeptides of the invention are not fibronectin or fragments of fibronectin such as the gelatin binding domain. Preferably, the fragments and variants and derivatives are those that include  
5 a portion or portions of MSF which are portions that distinguish MSF from fibronectin and which are described in more detail below and by reference to Figure 2.

Preferably, the polypeptide of the invention is one which has migration  
10 stimulating factor activity.

Further aspects of the invention provide antibodies which are selective for MSF (and do not cross react with fibronectin) and antibodies which are selective for fibronectin (and do not cross react with MSF).

15 By "selective" we include antibodies which bind at least 10-fold more strongly to one polypeptide than to the other (ie MSF vs fibronectin); preferably at least 50-fold more strongly and more preferably at least 100-fold more strongly.

20 Such antibodies may be made by methods well known in the art using the information concerning the differences in amino acid sequence between MSF and fibronectin disclosed herein. In particular, the antibodies may be polyclonal or monoclonal.

25 Suitable monoclonal antibodies which are reactive as said may be prepared by known techniques, for example those disclosed in "*Monoclonal Antibodies: A manual of techniques*", H Zola (CRC Press, 1988) and in "Monoclonal Hybridoma Antibodies: Techniques and Applications", SGR



Hurrell (CRC Press, 1982). Polyclonal antibodies may be produced which are polyspecific or monospecific. It is preferred that they are monospecific.

One embodiment provides an antibody reactive towards the polypeptide  
5 whose amino acid sequence is

```

N L V A T C L P V R A S L P H R L N
M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K
R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q
10 I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K
P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I
W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I
G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K
P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M
15 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y
R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C
E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P
Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q
M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C
20 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T
V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T
S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A
H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R
C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y
25 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C
D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y
Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F
I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W
R P V S I P P R N L G Y
30 (SEQ ID NO: 1)
```

or natural variants thereof but not reactive towards fibronectin.

A further embodiment provides an antibody reactive towards the polypeptide whose amino acid sequence is shown in Figure 2 labelled  
35 pMSF1I between positions 19 and 660 (SEQ ID NO: 2) or natural variants thereof but not reactive towards fibronectin.

A further embodiment provides an antibody reactive towards an epitope present in the polypeptide whose amino acid sequence is shown in Figure 2  
40 labelled pMSF1I or natural variants thereof but which epitope is not present in fibronectin.

A further embodiment provides an antibody reactive towards an epitope present in the polypeptide whose amino acid sequence is

```

5  N L V A T C L P V R A S L P H R L N
   M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K
   R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q
   I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K
   P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I
10  W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I
   G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K
   P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M
   V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y
   R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C
15  E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P
   Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q
   M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C
   V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T
   V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T
20  S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A
   H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R
   C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y
   N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C
   D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y
25  Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F
   I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W
   R P V S I P P R N L G Y

```

(SEQ ID NO: 1)

between positions 19 and 660 or natural variants thereof but which is epitope is not present in fibronectin.

30

It is particularly preferred if the antibody is reactive towards a molecule comprising any one of the peptides:

```

35  I S K Y I L R W R P V S I P P R N L G Y (SEQ ID NO: 35); or
     Q Q W E R T Y L G N A L V C T C Y G G S R (SEQ ID NO: 46); or
     P C V L P F T Y N D R T D S T T S N Y E Q D Q (SEQ ID NO: 57); or
     T D H T V L V Q T R G G N S N G A L C H (SEQ ID NO: 68); or
     V G N G R G E W T C I A Y S Q L R D Q C I (SEQ ID NO: 79)

```

which are found in MSF. The underlined amino acid(s) indicate the difference between MSF and fibronectin.

40

These peptides contain and flank regions of difference in amino acid sequence between MSF and fibronectin as shown in Figure 2 which are

believed to be useful in distinguishing MSF and fibronectin using antibodies.

A further embodiment provides an antibody reactive towards fibronectin but  
5 not reactive towards the polypeptide whose amino acid sequence is shown in  
Figure 2 labelled pMSF1 or natural variants thereof.

A further embodiment provides an antibody reactive towards fibronectin but  
not reactive towards the polypeptide whose amino acid sequence is shown in  
10 Figure 2 labelled pMSF1 between positions 19 and 660 (SEQ ID NO: 2) or  
natural variants thereof.

A further embodiment provides an antibody reactive towards an epitope  
present in fibronectin but not present in the polypeptide whose amino acid  
15 sequence is

N L V A T C L P V R A S L P H R L N  
M L R G P G P G L L L A V Q C L G T A V P S T G A S K S K  
20 R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
25 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
30 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
35 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
R P V S I P P R N L G Y

40 (SEQ ID NO: 1)

or natural variants thereof.

A further embodiment provides an antibody reactive towards an epitope present in fibronectin but not present in the polypeptide whose amino acid sequence is shown in Figure 2 labelled pMSF1I between positions 19 and 660 (SEQ ID NO: 2) or natural variants thereof.

5

It is particularly preferred if the antibody is reactive towards a molecule comprising any one of the peptides:

QQWERTYLGNVLVCTCYGGSR (SEQ ID NO: 810) or  
EPCVLPFTYNGRTFYSCTTEGRQDGHLWCSTTSNYEQDQ

10

(SEQ ID NO: 911) or

CTDHTVLVQTQGGNSNGALCH (SEQ ID NO: 4012) or  
VGNGRGEWTCYAYSQLRDQCI (SEQ ID NO: 413) or  
ISKYILRWRPKNSVGRWKEA (SEQ ID NO: 4314) or

15

peptides derived from position 648 onwards in fibronectin (SEQ ID NO: 15)  
as shown in Figure 2. The underlined amino acid(s) indicate the difference between fibronectin and MSF.

20

These peptides themselves may be useful for raising antibodies, but selective antibodies may be made using smaller fragments of these peptides which contain the region of difference between MSF and fibronectin.

25

Peptides in which one or more of the amino acid residues are chemically modified, before or after the peptide is synthesised, may be used providing that the function of the peptide, namely the production of specific antibodies *in vivo*, remains substantially unchanged. Such modifications include forming salts with acids or bases, especially physiologically acceptable organic or inorganic acids and bases, forming an ester or amide of a terminal carboxyl group, and attaching amino acid protecting groups such as N-t-butoxycarbonyl. Such modifications may protect the peptide from *in vivo*

metabolism. The peptides may be present as single copies or as multiples, for example tandem repeats. Such tandem or multiple repeats may be sufficiently antigenic themselves to obviate the use of a carrier. It may be advantageous for the peptide to be formed as a loop, with the N-terminal  
5 and C-terminal ends joined together, or to add one or more Cys residues to an end to increase antigenicity and/or to allow disulphide bonds to be formed. If the peptide is covalently linked to a carrier, preferably a polypeptide, then the arrangement is preferably such that the peptide of the invention forms a loop.

10

According to current immunological theories, a carrier function should be present in any immunogenic formulation in order to stimulate, or enhance stimulation of, the immune system. It is thought that the best carriers embody (or, together with the antigen, create) a T-cell epitope. The peptides  
15 may be associated, for example by cross-linking, with a separate carrier, such as serum albumins, myoglobins, bacterial toxoids and keyhole limpet haemocyanin. More recently developed carriers which induce T-cell help in the immune response include the hepatitis-B core antigen (also called the nucleocapsid protein), presumed T-cell epitopes such as Thr-Ala-Ser-Gly-  
20 Val-Ala-Glu-Thr-Thr-Asn-Cys (SEQ ID NO: ~~1316~~ 1316), beta-galactosidase and the 163-171 peptide of interleukin-1. The latter compound may variously be regarded as a carrier or as an adjuvant or as both. Alternatively, several copies of the same or different peptides of the invention may be cross-linked to one another; in this situation there is no separate carrier as such, but a  
25 carrier function may be provided by such cross-linking. Suitable cross-linking agents include those listed as such in the Sigma and Pierce catalogues, for example glutaraldehyde, carbodiimide and succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, the latter agent exploiting the -SH group on the C-terminal cysteine residue (if present).

If the peptide is prepared by expression of a suitable nucleotide sequence in a suitable host, then it may be advantageous to express the peptide as a fusion product with a peptide sequence which acts as a carrier. Kabigen's  
5 "Ecosec" system is an example of such an arrangement.

The peptide of the invention may be linked to other antigens to provide a dual effect.

10 A further aspect of the invention provides a method of making an antibody which is reactive towards the polypeptide whose amino acid sequence is

```

N L V A T C L P V R A S L P H R L N
M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K
15 R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q
I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K
P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I
W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I
G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K
20 P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M
V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y
R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C
E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P
Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q
25 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C
V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T
V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T
S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A
H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R
30 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y
N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C
D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y
Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F
I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W
35 R P V S I P P R N L G Y
```

(SEQ ID NO: 1)

or a natural variant thereof and which is not reactive with fibronectin, the method comprising the steps of, where appropriate, immunising an animal with a peptide which distinguishes MSF from fibronectin and selecting an  
40 antibody which binds MSF but does not substantially bind fibronectin. Suitable peptides are disclosed above.

A still further aspect of the invention provides a method of making an antibody which is reactive towards fibronectin and which is not reactive towards the polypeptide whose amino acid sequence is [SEQ ID NO: 1]

```
5  N L V A T C L P V R A S L P H R L N
   M L R G P G P G L L L A V Q C L G T A V P S T G A S K S K
   R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q
   I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K
10  P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I
   W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I
   G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K
   P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M
   V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y
   R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C
15  E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P
   Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q
   M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C
   V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T
   V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T
20  S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A
   H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R
   C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y
   N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C
   D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y
25  Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F
   I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W
   R P V S I P P R N L G Y
```

(SEQ ID NO: 1)

or a natural variant thereof, the method comprising the steps of, where appropriate, immunising an animal with a peptide which distinguishes fibronectin from MSF and selecting an antibody which binds fibronectin but does not substantially bind MSF. Suitable peptides are disclosed above.

It will be appreciated that, with the advancements in antibody technology, it may not be necessary to immunise an animal in order to produce an antibody. Synthetic systems, such as phage display libraries, may be used. The use of such systems is included in the methods of the invention.

Before the present invention it was not possible to make use of the differences in amino acid sequence between fibronectin and MSF in order to make antibodies which are useful in distinguishing MSF and fibronectin since it was not known that MSF and fibronectin had significant differences

in structure or what those differences were. As is discussed in more detail below, such antibodies are useful in cancer diagnosis. It will also be appreciated that such antibodies which distinguish MSF and fibronectin are also useful research reagents. Suitably, the antibodies of the invention are  
5 detectably labelled, for example they may be labelled in such a way that they may be directly or indirectly detected. Conveniently, the antibodies are labelled with a radioactive moiety or a coloured moiety or a fluorescent moiety, or they may be linked to an enzyme. Typically, the enzyme is one which can convert a non-coloured (or non-fluorescent) substrate to a  
10 coloured (or fluorescent) product. The antibody may be labelled by biotin (or streptavidin) and then detected indirectly using streptavidin (or biotin) which has been labelled with a radioactive moiety or a coloured moiety or a fluorescent moiety, or the like or they may be linked to an enzyme of the type described above.

15

It is particularly preferred if peptides are made, based on the amino acid sequence of MSF and fibronectin, which allow for specific antibodies to be made.

20 Thus, a further aspect of the invention provides a molecule which is capable of, following immunisation of an animal if appropriate, giving rise to antibodies which are reactive towards the polypeptide whose sequence is

25 N L V A T C L P V R A S L P H R L N  
M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K  
R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
30 G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
35 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T



V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 5 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

10 (SEQ ID NO: 1)\_

or natural variants thereof but not reactive towards fibronectin.

A still further aspect of the invention provides a molecule which is capable  
 of, following immunisation of an animal if appropriate, giving rise to  
 15 antibodies which are reactive towards fibronectin but not reactive towards  
 the polypeptide whose sequence is

N L V A T C L P V R A S L P H R L N  
 M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K  
 R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
 20 I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
 P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
 W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
 G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
 P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
 25 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
 E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
 30 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 35 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

40 (SEQ ID NO: 1)

or natural variants thereof.

The molecule is preferably a peptide but may be any molecule which gives  
 rise to the desired antibodies. The molecule, preferably a peptide, is  
 45 conveniently formulated into an immunological composition using methods  
 well known in the art.

The peptides disclosed above form part of these aspects of the invention.

Peptides may be synthesised by the Fmoc-polyamide mode of solid-phase peptide synthesis as disclosed by Lu *et al* (1981) *J. Org. Chem.* **46**, 3433  
5 and references therein. Temporary N-amino group protection is afforded by the 9-fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive cleavage of this highly base-labile protecting group is effected using 20% piperidine in N,N-dimethylformamide. Side-chain functionalities may be protected as their butyl ethers (in the case of serine threonine and tyrosine), butyl esters  
10 (in the case of glutamic acid and aspartic acid), butyloxycarbonyl derivative (in the case of lysine and histidine), trityl derivative (in the case of cysteine) and 4-methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case of arginine). Where glutamine or asparagine are C-terminal residues, use is made of the 4,4'-dimethoxybenzhydryl group for protection of the side chain  
15 amido functionalities. The solid-phase support is based on a polydimethylacrylamide polymer constituted from the three monomers dimethylacrylamide (backbone-monomer), bisacryloylethylene diamine (cross linker) and acryloylsarcosine methyl ester (functionalising agent). The peptide-to-resin cleavable linked agent used is the acid-labile 4-  
20 hydroxymethyl-phenoxyacetic acid derivative. All amino acid derivatives are added as their preformed symmetrical anhydride derivatives with the exception of asparagine and glutamine, which are added using a reversed N,N-dicyclohexyl-carbodiimide/1-hydroxybenzotriazole mediated coupling procedure. All coupling and deprotection reactions are monitored using  
25 ninhydrin, trinitrobenzene sulphonic acid or isotin test procedures. Upon completion of synthesis, peptides are cleaved from the resin support with concomitant removal of side-chain protecting groups by treatment with 95% trifluoroacetic acid containing a 50% scavenger mix. Scavengers commonly used are ethanedithiol, phenol, anisole and water, the exact choice

depending on the constituent amino acids of the peptide being synthesised. Trifluoroacetic acid is removed by evaporation *in vacuo*, with subsequent trituration with diethyl ether affording the crude peptide. Any scavengers present are removed by a simple extraction procedure which on

5 lyophilisation of the aqueous phase affords the crude peptide free of scavengers. Reagents for peptide synthesis are generally available from Calbiochem-Novabiochem (UK) Ltd, Nottingham NG7 2QJ, UK. Purification may be effected by any one, or a combination of, techniques such as size exclusion chromatography, ion-exchange chromatography and

10 (principally) reverse-phase high performance liquid chromatography. Analysis of peptides may be carried out using thin layer chromatography, reverse-phase high performance liquid chromatography, amino-acid analysis after acid hydrolysis and by fast atom bombardment (FAB) mass spectrometric analysis.

15

It is now possible to make polynucleotides which can distinguish MSF and fibronectin and such polynucleotides are believed to be useful in the diagnosis and prognosis of cancer.

20 A further aspect of the invention provides a polynucleotide which is capable of distinguishing a polynucleotide which encodes the polypeptide whose sequence is

25 N L V A T C L P V R A S L P H R L N  
 M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K  
 R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
 I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
 P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
 W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
 30 G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
 P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
 E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
 35 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T

5 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

10 (SEQ ID NO: 1)

or a natural variant thereof and a polynucleotide which encodes fibronectin.

A still further aspect of the invention provides a polynucleotide which is capable of hybridising to a polynucleotide which encodes fibronectin but not

15 a polynucleotide which encodes the polypeptide whose sequence is

20 N L V A T C L P V R A S L P H R L N  
 M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K  
 R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
 I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
 P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
 W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
 G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
 P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
 25 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
 E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
 30 V L V P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 35 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

40 (SEQ ID NO: 1)

or a natural variant thereof.

A yet still further aspect of the invention provides a polynucleotide which is capable of hybridising to a polynucleotide which encodes the polypeptide

45 which encodes the polypeptide whose sequence is

N L V A T C L P V R A S L P H R L N  
 M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K

5 R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
 I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
 P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
 W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
 10 G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
 P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
 E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
 15 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 20 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 25 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

(SEQ ID NO: 1)

or a natural variant thereof but not to a polynucleotide which encodes fibronectin.

25

Such polynucleotides can be designed by reference to Figures 1 and 2 and  
 the known sequence of fibronectin (SEQ ID NO: 17) (Kornblihtt *et al*  
 (1985) *EMBO J.* 4, 1755-1759), and may be synthesised by well known  
 methods such as by chemical synthesis or by using specific primers and  
 30 template, a DNA amplification technique such as the polymerase chain  
 reaction. The polynucleotide may be any polynucleotide, whether DNA or  
 RNA or a synthetic nucleic acid such as a peptide nucleic acid, provided that  
 it can distinguish polynucleotides which encode MSF and fibronectin as  
 said. It is particularly preferred if the polynucleotide is an oligonucleotide  
 35 which can serve as a hybridisation probe or as a primer for a nucleic acid  
 amplification system. Thus, the polynucleotide of this aspect of the  
 invention may be an oligonucleotide of at least 10 nucleotides in length,  
 more preferably at least 14 nucleotides in length and still more preferably at  
 least 18 nucleotides in length.

40

It is particularly preferred that the polynucleotide hybridises to a mRNA (or cDNA) which encodes MSF but does not hybridise to a mRNA (or cDNA) which encodes fibronectin.

- 5 It is also particularly preferred that the polynucleotide hybridises to a mRNA (or cDNA) which encodes fibronectin but does not hybridise to a mRNA (or cDNA) which encodes MSF. The nucleotide sequence of MSF cDNA is disclosed herein and the nucleotide sequence of fibronectin is known (for example, see Kornblihtt *et al* (1985) *EMBO J.* 4, 1755-1759). The skilled person can readily design probes which can distinguish MSF and fibronectin mRNAs and cDNAs based on this information. Differences between MSF and fibronectin include a 45 bp deletion from the first type II fibronectin repeat module in MSF, and the unique tail present in MSF.
- 10
- 15 Preferably, the polynucleotides of the invention are detectably labelled. For example, they may be labelled in such a way that they may be directly or indirectly detected. Conveniently, the polynucleotides are labelled with a radioactive moiety or a coloured moiety or a fluorescent moiety or some other suitable detectable moiety. The polynucleotides may be linked to an enzyme, or they may be linked to biotin (or ~~streptavidin~~streptavidin) and detected in a similar way as described for antibodies of the invention.
- 20

A further aspect of the invention provides a method of diagnosing cancer the method comprising detecting in a sample from the person to be diagnosed the presence of a polypeptide whose sequence is

25

30 N L V A T C L P V R A S L P H R L N  
M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K  
R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K

P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
 E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
 5 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 10 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 15 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

(SEQ ID NO: 1)

or a natural variant or fragment thereof using a reagent which can distinguish said polypeptide from fibronectin.

20

A still further aspect of the invention provides a method of determining susceptibility to cancer the method comprising detecting in a sample derived from the person to be tested the presence of a polypeptide whose sequence is

25

N L V A T C L P V R A S L P H R L N  
 M L R G P G P G L L L A V Q C L G T A V P S T G A S K S K  
 R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
 I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
 30 P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
 W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
 G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
 P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
 35 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
 E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
 40 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 45 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

(SEQ ID NO: 1)

50 or a natural variant or fragment thereof using a reagent which can distinguish said polypeptide from fibronectin.

A still further aspect of the invention provides a method of determining the likely outcome of a patient with cancer the method comprising detecting in a sample from the patient the presence of a polypeptide whose sequence is

5  
N L V A T C L P V R A S L P H R L N  
M L R G P G P G L L L A V Q C L G T A V P S T G A S K S K  
R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
10 P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
15 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
20 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
25 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
R P V S I P P R N L G Y

(SEQ ID NO: 1)

30 or a natural variant or fragment thereof using a reagent which can distinguish said polypeptide from fibronectin.

Preferably, the reagent which can distinguish MSF from fibronectin is an antibody as disclosed herein. The use of antibodies to detect specific polypeptides in samples is well known. For example, they can be used in enzyme-linked immunosorbent assays (ELISA) or they may be used in histopathological analysis. It is believed that the presence of MSF indicates an elevated risk of cancer.

40 MSF may be conveniently measured in suitable body fluids such as serum or urine, or in extracts of tissue, or in the medium used to culture patient derived cells *in vitro*.



The measurement of MSF is believed to be useful in a number of cancers as discussed above. Antibodies may be used to detect MSF in tissue sections by immunolocalisation. Sub-populations of MSF-producing fibroblasts are present in the normal adult (Irwin *et al* (1994) *J. Cell Science* 107, 1333-1346; Schor *et al* (1994) pp 277-298 in *Mammary Tumorigenesis and Malignant Progression*, Dickson, R. and Lippman, M. (eds), 1994, Kluwer Academic Publishers.

It will be appreciated that, as well as the MSF polypeptide being measured using the methods described herein in diagnosis or prognosis or determination of susceptibility to cancer, it may be desirable to detect MSF mRNA in a suitable sample or it may be desirable to detect any changes in the fibronectin gene which are associated with the production of MSF. Mutations in the MSF cDNA or fibronectin gene may be detected using methods well known in the art.

Thus, a further aspect of the invention provides a method of determining susceptibility to cancer the method comprising detecting in a sample derived from the person to be tested the presence of a polynucleotide encoding a polypeptide whose sequence is

```

N L V A T C L P V R A S L P H R L N
M L R G P G P G L L L L A V Q C L G T A V P S T G A S K S K
25 R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q
I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K
P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I
W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I
G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K
30 P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M
V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y
R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C
E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P
Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q
35 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C
V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T
V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T
S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A

```

H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 5 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

(SEQ ID NO: 1)

or a natural variant or fragment thereof using a reagent which can  
 10 distinguish said polynucleotide from a polynucleotide encoding fibronectin.

A still further aspect of the invention provides a method of determining the  
 likely outcome of a patient with cancer the method comprising detecting in a  
 sample from the patient the presence of a polynucleotide encoding a  
 15 polypeptide whose sequence is

N L V A T C L P V R A S L P H R L N  
 M L R G P G P G L L L A V Q C L G T A V P S T G A S K S K  
 R Q A Q Q M V Q P Q S P V A V S Q S K P G C Y D N G K H Y Q  
 20 I N Q Q W E R T Y L G N A L V C T C Y G G S R G F N C E S K  
 P E A E E T C F D K Y T G N T Y R V G D T Y E R P K D S M I  
 W D C T C I G A G R G R I S C T I A N R C H E G G Q S Y K I  
 G D T W R R P H E T G G Y M L E C V C L G N G K G E W T C K  
 P I A E K C F D H A A G T S Y V V G E T W E K P Y Q G W M M  
 25 V D C T C L G E G S G R I T C T S R N R C N D Q D T R T S Y  
 R I G D T W S K K D N R G N L L Q C I C T G N G R G E W K C  
 E R H T S V Q T T S S G S G P F T D V R A A V Y Q P Q P H P  
 Q P P P Y G H C V T D S G V V Y S V G M Q W L K T Q G N K Q  
 M L C T C L G N G V S C Q E T A V T Q T Y G G N S N G E P C  
 30 V L P F T Y N D R T D S T T S N Y E Q D Q K Y S F C T D H T  
 V L V Q T R G G N S N G A L C H F P F L Y N N H N Y T D C T  
 S E G R R D N M K W C G T T Q N Y D A D Q K F G F C P M A A  
 H E E I C T T N E G V M Y R I G D Q W D K Q H D M G H M M R  
 C T C V G N G R G E W T C I A Y S Q L R D Q C I V D D I T Y  
 35 N V N D T F H K R H E E G H M L N C T C F G Q G R G R W K C  
 D P V D Q C Q D S E T G T F Y Q I G D S W E K Y V H G V R Y  
 Q C Y C Y G R G I G E W H C Q P L Q T Y P S S S G P V E V F  
 I T E T P S Q P N S H P I Q W N A P Q P S H I S K Y I L R W  
 R P V S I P P R N L G Y

40 (SEQ ID NO: 1)

or a natural variant or fragment thereof using a reagent which can  
 distinguish said polynucleotide from a polynucleotide encoding fibronectin.

Preferably, the reagent which can distinguish the polynucleotide encoding  
 45 MSF from the polynucleotide encoding fibronectin is a suitable  
 polynucleotide as disclosed herein. Methods of detecting specific nucleic

acids in a sample are well known in the art. For example, *in situ* hybridisation methods which detect mRNA may be used, and northern blotting methods may be used. Dot blots, slot blots and Southern blots may also be used.

5

Thus, it can be seen that the reagents used in the above methods may be used in the manufacture of a reagent for diagnosing cancer.

It will be appreciated that the antibodies of the invention, and the  
10 polynucleotides of the invention, which can distinguish MSF and fibronectin (particularly those which recognise MSF or a nucleic acid encoding MSF, but not fibronectin, or a nucleic acid encoding fibronectin) are useful packaged into diagnostic kits containing said antibodies or polynucleotides and other reagents such as means for labelling the said antibodies or  
15 polynucleotides.

The invention also includes a number of therapeutic applications, for example chemoprevention and chemotherapy.

20 Chemoprevention includes the neutralisation of MSF activity and/or the suppression of inappropriate MSF expression in individuals deemed to be at risk of cancer due to inappropriate MSF production. It may also be desirable to administer inhibitors of MSF. Antibodies directed at MSF may act as inhibitors.

25

Chemotherapy includes the use of anti-MSF antibodies to target coupled cytotoxins to sites of inappropriate MSF production, and the use of MSF inhibitors as mentioned above.

Antibody-targeted cytotoxins are well known in the art and include antibodies linked to a directly cytotoxic moiety such as ricin or a toxic drug; and antibodies linked to an indirectly cytotoxic moiety such as an enzyme which is able to convert a non-toxic prodrug into a toxic drug. In the latter  
5 case, the prodrug as well as the antibody-linked enzyme is administered to the patient.

It is useful to measure MSF in wound fluids since this information may be relevant in terms of predicting the efficiency of the subsequent healing  
10 process, including the propensity of the scar. The amount of MSF in wound fluids may be measured using, for example, an MSF-selective antibody of the invention.

Inappropriate expression of MSF may be a feature of several pathological  
15 conditions characterised by inflammation, such as rheumatoid arthritis. The measurement of MSF in associated body fluid, such as synovial fluid, may be of clinical utility; other pathological conditions of relevance in this context include fibrotic and periodontal disease.

20 MSF is believed to be involved in the migration of cells, especially fibroblasts any, in particular, the migration of cells may take place within the wound.

Thus, a further aspect of the invention provides a method of modulating cell  
25 migration the method comprising administering an effective amount of a polypeptide of the invention to the site where modulation of cell migration is required.

Typically, the cell whose migration is modulated is a fibroblast. Typically, MSF stimulates the migration of cells such as fibroblasts. Preferably, the site where modulation of cell migration is required is a site within a mammalian body, such as the body of a horse, pig, cow, sheep, cat, dog and  
5 the like. Most preferably it is a site within a human body. It is preferred if the site within the body is the site of a wound.

A further aspect of the invention provides a method of healing a wound the method comprising administering to the locality of the wound an effective  
10 amount of a polypeptide of the invention.

The invention also includes a method of preventing scarring by administering to the locality of the site where scarring is believed to be likely an effective amount of an MSF polypeptide as described herein or a  
15 suitable fragment or variant. Preventing or reducing scarring may be part of the wound-healing process. The MSF polypeptide as described herein or a suitable fragment or variant is believed to be useful in preventing or reducing scarring because it reduces hyaluronic acid formation.

20 It is preferred if the polypeptide administered is a recombinant polypeptide expressed in a eukaryotic host.

The MSF polypeptide may be administered to the site of cell migration or wound healing by any suitable means. Conveniently, the polypeptide is  
25 administered topically. It is particularly preferred if the polypeptide is incorporated within an applied wound dressing such as a collagen mesh. Dressings which are suitable for the incorporation of the polypeptide of the invention are well known in the art and many are commercially available.

Other formulations might involve the incorporation of MSF into an ointment, paste, gel, cream (or equivalent) designed for topical application.

The formulations may conveniently be presented in unit dosage form and  
5 may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient (polypeptide of the invention) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient  
10 with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

Formulations in accordance with the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets  
15 or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

20

Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and  
25 mouth-washes comprising the active ingredient in a suitable liquid carrier.

It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in

question, for example those suitable for oral administration may include flavouring agents.

Application of gene therapy techniques may provide a means of controlling  
5 MSF expression.

Any suitable amount of the polypeptide of the invention may be administered. By "suitable amount" we mean an amount which gives the desired biological response and that does not lead to any significantly  
10 undesirable effects such as toxicity or the like. Small quantities of MSF, for example less than 1 Tg, may be effective. It is preferred if superficial wounds, such as those to the skin, are treated by the method of the invention.

15 The invention will now be described in further detail with reference to the following Figures and Examples wherein:

Figure 1 shows the entire nucleotide sequence of the 2.1kb insert in clone pMSF1I which contains the MSF cDNA. The start and stop codons are underlined.

20

Figure 2 shows the translation of the cDNA sequence shown in Figure 1 and the alignment of the peptide sequence with that of the gelatin-binding domain of fibronectin. The start and end of the MSF polypeptide are indicated by vertical bars and arrows.

25

Figure 3 shows the peptide sequence of MSF (as encoded in the pMSF1I clone) according to its domains. The sequence of pMSF1I is shown grouped according to its domains (cf analysis of fibronectin from Kornblihtt *et al* (1985) *EMBO J.* 4, 1755-1759). Residues are numbered and have been

aligned to give optimal homology by introducing gaps (indicated by ^). Identical residues within a type of homology are indicated by a box (A), and stop codons are designated by asterisks (\*). Deleted amino acids are indicated by dashed lines (-), and the IGDS sequence is underlined.

5

Figure 4 shows a diagrammatic comparison of fibronectin and MSF.

Figure 5 shows a diagrammatic model of MSF showing the positions of the IGD-containing sequences (ie. IGDT, IGDS and IGDQ) within the domains.

10

***Example 1: Cloning and sequence analysis of pMSF1I, a clone encoding MSF***

A cDNA library was constructed using mRNA extracted from a human  
15 foetal fibroblast cell line, MRC5-SV2, in the vector  $\lambda$ ZapII.

A primer based on peptide sequence from the gelatin-binding domain (GBD) of fibronectin was used together with a vector primer in the polymerase chain reaction (PCR) to amplify a fragment of 1.2kb. Sequence  
20 analysis showed a strong homology to GBD for most of the fragment. Clear differences included an internal deletion of 45bp, and a 3' unique sequence of 175bp.

The 3' unique sequence was used as a probe for screening the library, using  
25 the digoxigenin-labelled system. Positive plaques were picked for further analysis by secondary and tertiary screening, followed by *in vivo* excision of the pBluescript™ phagemid containing the cloned insert.



A plasmid containing an insert of 2.1kb, named pMSF1I, was sequenced by the Sanger-dideoxy method, using a progressive priming approach, and the sequence was assembled into a single contain using the Fragment Assembly System of the Daresbury/Seqnet series of programs.

5

The entire nucleotide sequence of the 2.1kb fragment is shown in Figure 1.

Translation of this sequence and alignment of its peptide sequence with that of the gelatin-binding domain of fibronectin was achieved using the Fasta program (Daresbury/Seqnet), and is shown in Figure 2.

10

Figure 3 shows the peptide sequence of pMSF-1I grouped according to its domains.

15 Other cDNA clones encoding MSF may be readily obtained and sequenced using methods well known in the art and probe derived from the Figure 1 sequence, in particular probes which distinguish MSF from fibronectin.

***Example 2: Demonstration of the presence of MSF-secreting fibroblasts in sections of breast cancer, but not normal breast tissue***

20

*In situ* hybridisation using a riboprobe based on the unique coding region for the unique C-terminus of MSF demonstrates the presence of MSF-secreting fibroblasts in sections of breast cancer, but not normal breast tissue.

25

Suitable riboprobes contain the entire unique nucleotide sequence of MSF-1I (position 1953-2147), and may include up to 10 bases upstream and contained within the fibronectin sequence (position 1943-2152). This ensures high specificity towards MSF-1I, whilst allowing the use of a probe

of longer length. A digoxigenin-labelled riboprobe containing a major portion of the unique sequence (position 1974-2147) is used. This region was selected on the basis of the position of convenient restriction sites.

5    ***Example 3: Monoclonal antibodies which are specific to MSF and do not cross-react with fibronectin***

Monoclonal antibodies are raised using any of the currently available standard procedures. The immunogen is a synthetic peptide based on the 10  
10    amino acid unique tail of MSF (VSIPPRNLGY (SEQ ID NO: 41)) or is based on the peptide sequences:

ISKYILRWRPVSIPPRNLGY (SEQ ID NO: 35); or  
QQWERTYLGNALVCTCYGGSR (SEQ ID NO: 46); or  
15    PCVLPFTYNDRTDSTTSNYEQDQ (SEQ ID NO: 57); or  
TDHTVLVQTRGGSNSNGALCH (SEQ ID NO: 68); or  
VGNGRGEWTCIAYSQRLRDQCI (SEQ ID NO: 79)

***Example 4: Genomic PCR and FISH studies***

20

*Objective:* To obtain information regarding the sequence of the genomic MSF gene regarding (i) its relationship to fibronectin, and (ii) chromosomal location.

25    *Background:* The 5' upstream untranslated sequence of the cloned MSF cDNA is identical to that of fibronectin, thereby strongly suggesting its close relationship to the fibronectin gene (note: such upstream untranslated regions are virtually never identical between two genes as there is no selective pressure. This inference is in apparent conflict with the  
30    "uniqueness" of the 3' end of the MSF cDNA which codes for a 10 amino

acid polypeptide and also contains a contiguous untranslated region containing several stop codons).

*Methods and Results:* Two PCR reactions were established: one at the  
5 extreme 5' untranslated region of fibronectin (FN)/MSF and the other at the  
extreme 3' region of MSF which encompassed the 175bp unique sequence.  
Reactions were carried out using DNA purified using the  
~~Qiagen~~ QIAGEN™ Blood kit. Sequence analysis of the resulting amplicon  
revealed that the 175bp "unique" sequence was contiguous with the  
10 fibronectin sequence.

Experiments were then carried out in order to obtain initial data regarding  
the genomic location of the 3' unique sequence. This was accomplished by  
selecting clones from the human PAC library (obtained from HGMP) using  
15 the above 2 PCR approach. Secondary and tertiary screening lead to the  
identification of one which produced products from *both* PCR reactions.  
This clone was approximately 70-110 kb in size.

The isolated clone was next subjected to restriction digestion (BamHI and  
20 KpnI) and the fragments subcloned into pBluescript and analysed using our  
2 PCR approach. Two positive clones were identified: clone B3(2) is 20 kb  
and can generate both the 5' and 3' fragments, thereby indicating that it  
contains the entire MSF genomic sequence. The other clone, K5(5) is 7 kb  
and only contains the 3' unique sequence.

25

We have used both clones for FISH analysis of the human genome. Our  
data unambiguously indicate that MSF maps to chromosome 2 region q35.  
Note: this is within the fibronectin gene, which is located on chromosome  
2q34-36.

*Conclusions:* The FISH analysis clearly indicates that the gene coding for the MSF “unique” sequence is contained within the fibronectin gene. These results indicate that MSF is a novel “mini” splice variant of fibronectin.

- 5 The genomic fibronectin gene is very large indeed and has still not been fully sequenced. To our knowledge, this is the first report of the unique sequence. The absence of the unique sequence in all previously identified isoforms of fibronectin (which are all in excess of 220 kDa compared to 70 kDa for MSF) indicates that it is spliced out of these molecules.

10

- This information is of relevance for several reasons. Firstly, all previously described splice variants of fibronectin have molecular masses in the region of 225 kDa compared with only 70 kDa of MSF. This small size is totally unexpected and prompts us to refer to MSF as a novel “mini” splice variant
- 15 of fibronectin. Secondly, all known splice variants of fibronectin involve the inclusion/deletion of entire type III repeats or variable regions of the IIICS region (all of which occur at a considerable distance downstream of the termination of MSF, which does not contain any known splice site). Finally, as the unique 3’-sequence of MSF was not hitherto identified, it was
- 20 not possible to predict that MSF was indeed a splice variant of fibronectin until the above data was obtained from genomic DNA.

#### ***Example 5: Recombinant MSF expression***

- 25 *Objective:* To express recombinant human MSF (rhMSF) in 3T3 cells.

*Methods and Results:* 3T3 cells were transfected using the ~~Lipfectamine~~ Lipofectamine/Plus system (Gibco), according to the manufacturer’s instructions. The plasmid used was pcDNA3.1/hisB/lacZ.

The insert sequence contained a sequence encoding a *his* tail fused to the human MSF cDNA sequence so that a fusion protein with a *his* tail is expressed. This facilitates purification of the expressed protein. Transfectants were isolated by their selective growth in medium containing

5 418. One liter of conditioned medium produced by the transfected cells was collected and the fraction containing all the migration stimulating activity obtained by doing a 0-20% ammonium sulphate precipitation. The pellet was resuspended in buffer and the *his*-tagged rhMSF purified by passage through a ProBond column (Invitrogen) column, all done in accordance with

10 manufacturer's instructions. Approximately 250 Tg of rhMSF were collected from the starting material. The purified protein resulted in a single band of approximately 70 kDa in SDS PAGE. This protein stimulated the migration of target adult fibroblasts and was active at concentrations between 1 pg/ml to 10 ng/ml (ie in precise agreement with previously

15 published data regarding the dose-response of MSF purified from fetal fibroblast conditioned medium).

#### ***Example 6: Anti-MSF antibody production***

20 ***Objective:*** To generate polyclonal antibodies to MSF.

***Methods:*** Rabbits were immunised with a 15-mer synthetic peptide based on the C-terminus of MSF: note, this contains the entire 10 amino acid unique sequence and the contiguous 5 amino sequence of fibronectin. The

25 synthetic peptide was coupled to keyhole limpet haemocyanin (KLH) carrier and used to immunise two rabbits with the following protocol: first injection of 10 mg and second injection of 5 mg three weeks later. Serum was collected six weeks after the first injection and purified IgG shown to recognise the synthetic peptide in both dot and Western blots.

*Results:* We have used the antibody for both Western blots and immunohistochemistry. The former application has (i) confirmed that rhMSF is recognised by the antibody, and (ii) demonstrated that fetal, but  
5 not adult, fibroblasts produce a 70 kDa molecule which is recognised by the antibody and expresses migration stimulating activity when eluted from the PAGE gels.

Polyclonal antibodies were generated against a synthetic peptide  
10 incorporating the 10 amino acid "unique" MSF C-terminal sequence. This antibody recognises the unique synthetic peptide (down to 5 ng) and MSF (down to 10 ng) in dot blots; it does not recognise fibronectin or BSA at concentrations up to 4 µg. This antibody has been used to investigate the tissue distribution of MSF; these experiments show that MSF is present in  
15 the stromal compartment of fetal skin and is not detectable in adult skin.

## ABSTRACT

### POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF

5

A recombinant polynucleotide encoding migrating stimulating factor (MSF) or variants or fragments or derivatives or fusions thereof or fusions of said variants or fragments or derivatives.

10

\_Reagents are disclosed which can distinguish MSF and fibronectin, and which can ~~dintinguish~~distinguish polynucleotides which encode MSF or fibronectin. These reagents are believed to be useful in, for example, diagnosing cancer.

15

\_MSF or variants or fragments or derivatives or fusions thereof, or fusions of said variants or fusions or derivatives, are useful in modulating cell migration and in wound healing.

20

H:\DOCS\CGT\CGT-6275.DOC  
0719041535237\_1  
040505  
1712548  
051405